Symbiotec Pharmalab Limited has provided prior intimation to BSE Limited and National Stock Exchange of India Limited regarding a scheduled meeting of the Board of Directors.
The Board meeting is scheduled for Monday, September 21, 2026. The primary agenda items include:
- Consideration and approval of the Unaudited Standalone Financial Results for the quarter ended June 30, 2026
- Consideration and approval of the Unaudited Consolidated Financial Results for the quarter ended June 30, 2026
- Review of the Limited Review Report accompanying the financial results
- Consideration of any other matter with the permission of the Chair
The company references its earlier intimation dated September 1, 2026, confirming that the 'Trading window' for dealing in securities of the Company remains closed for all designated persons and their immediate relatives. This closure will continue until 48 hours after the declaration of the financial results.
This information is available on the company's website at www.symbiotec.com.
The disclosure is signed by Salil Jain, Company Secretary and Compliance Officer (Membership No. A41610), and includes the company's registered office details at 385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India. Company CIN: U24232MP2002PLC015293.